{"id":6364,"date":"2011-11-24T18:54:55","date_gmt":"2011-11-24T17:54:55","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/"},"modified":"2026-10-17T11:23:01","modified_gmt":"2026-10-17T10:23:01","slug":"vemurafenib-2","status":"publish","type":"page","link":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/","title":{"rendered":"Vemurafenib in melanoma"},"content":{"rendered":"<div class=\"im26-diagnosis-guide\">\n<aside class=\"im26-dg-related\"><strong>How to read this guide<\/strong><\/p>\n<p>Educational information based on the cited sources, not an individual prescription. Editorial revision is not equivalent to specialist clinical validation. Decisions and treatments must be agreed with the treating team; benefits, risks and availability depend on the case.<\/p>\n<\/aside>\n<nav class=\"im26-dg-toc\" aria-label=\"On this page\"><strong>On this page<\/strong><\/p>\n<ol>\n<li><a href=\"#med-bersaglio\">The BRAF target and molecular selection<\/a><\/li>\n<li><a href=\"#med-evidenze\">BRIM-3 and the move to dual inhibition<\/a><\/li>\n<li><a href=\"#med-rischi\">Skin checks and general safety<\/a><\/li>\n<li><a href=\"#med-limiti\">Resistance, sequencing and experimental combinations<\/a><\/li>\n<\/ol>\n<\/nav>\n<section class=\"im26-dg-section\" id=\"med-bersaglio\">\n<h2>The BRAF target and molecular selection<\/h2>\n<p>Vemurafenib, also known by the brand Zelboraf and development codes PLX4032\/RG7204, inhibits mutated BRAF protein. It interferes with growth signalling through the MAPK pathway. It is not indicated indiscriminately for every melanoma: a BRAF V600 mutation must be documented with a validated test.<\/p>\n<p><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/\">BRAF V600E<\/a> was central to early development, but the European indication should not be reduced to the name of one commercial assay. The report must specify the variant and a specialist assesses its meaning. A molecular result does not replace histological diagnosis, <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/\">staging<\/a> or assessment of alternatives.<\/p>\n<div class=\"im26-dg-gallery\">\n<figure><a href=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png\"><img loading=\"lazy\" src=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png\" width=\"800\" height=\"470\" loading=\"lazy\" decoding=\"async\" alt=\"Molecular structure of vemurafenib: an illustration from the site archive.\"\/><\/a><figcaption>Molecular structure of vemurafenib: an illustration from the site archive.<\/figcaption><\/figure>\n<\/div>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/13961\/\">NCBI ClinVar \u2014 BRAF c.1799T&gt;A, p.Val600Glu<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-evidenze\">\n<h2>BRIM-3 and the move to dual inhibition<\/h2>\n<p>BRIM-3, published in 2011, compared vemurafenib with dacarbazine in previously untreated BRAF V600E <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/common-types-of-melanoma\/metastatic-melanoma\/\">metastatic melanoma<\/a>. The observed benefit helped establish targeted treatment. These results belong to a specific period and comparison: they do not automatically describe benefit against immunotherapies available today.<\/p>\n<p>The subsequent coBRIM trial assessed adding <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\">cobimetinib<\/a>, a MEK inhibitor, and showed better progression control than vemurafenib alone. BRAF\/MEK combinations have taken a central role when targeted treatment is selected. Any monotherapy use requires clinical context and should not be inferred from older webpages or the medicine\u2019s availability alone.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21639808\/\">Chapman et al. \u2014 BRIM-3, randomized phase 3 (2011)<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25265494\/\">Larkin et al. \u2014 coBRIM, randomized phase 3 (2014)<\/a>; <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-rischi\">\n<h2>Skin checks and general safety<\/h2>\n<p>Vemurafenib can cause photosensitivity, rashes, joint pain and other effects. Sun protection and dermatological checks are important, including for detecting new lesions, skin carcinomas or keratoacanthomas. A new lesion should be assessed rather than self-diagnosed.<\/p>\n<p>Monitoring also addresses liver and cardiac issues and interactions with other medicines according to the centre\u2019s plan and product information. QT-interval prolongation is one risk to consider. Report all medicines, herbal products and supplements. Dose, timing and management of a missed dose must follow the prescription and current leaflet, not a schedule reconstructed from an educational webpage.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>.<\/small><\/p>\n<\/section>\n<section class=\"im26-dg-section\" id=\"med-limiti\">\n<h2>Resistance, sequencing and experimental combinations<\/h2>\n<p>A tumour can develop resistance even after an initial response. Progression does not mean every option is exhausted: disease sites, symptoms, previous treatments and subsequent options need reassessment. Sequencing trials inform discussion without justifying self-directed treatment changes.<\/p>\n<p>Concurrent combination with <a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/\">ipilimumab<\/a> is not a routine proposal: an early trial reported liver toxicity. Not every biologically plausible combination is safe. New uses or combinations outside established regimens must be assessed within their research or specific-access setting, distinguished from the vemurafenib\u2013cobimetinib pair authorised for advanced disease.<\/p>\n<p class=\"im26-dg-sources\"><small>Sources for this section: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23550685\/\">Ribas et al. \u2014 Hepatotoxicity with vemurafenib + ipilimumab (2013)<\/a>; <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9839305\/\">DREAMseq \u2014 Randomized treatment-sequence trial (2022\/2023)<\/a>; <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a>; <a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a>.<\/small><\/p>\n<\/section>\n<aside class=\"im26-dg-related\">\n<h2>Continue reading<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/\">Medical treatment of melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/drugs-approved-for-melanoma\/\">Approved medicines for melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/braf-v600e\/\">BRAF V600E in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/ipilimumab-yervoy\/\">Ipilimumab in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/cobimetinib\/\">Cobimetinib in melanoma<\/a><\/li>\n<li><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/dabrafenib-and-trametinib\/\">Dabrafenib and trametinib in melanoma<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/#med-sperimentali\">Experimental treatments: evidence, limitations and trial access<\/a><\/p>\n<\/aside>\n<section class=\"im26-dg-sources\">\n<h2>Sources and update<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelboraf\">EMA \u2014 Zelboraf: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/13961\/\">NCBI ClinVar \u2014 BRAF c.1799T&gt;A, p.Val600Glu<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21639808\/\">Chapman et al. \u2014 BRIM-3, randomized phase 3 (2011)<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25265494\/\">Larkin et al. \u2014 coBRIM, randomized phase 3 (2014)<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/\">ESMO \u2014 Cutaneous melanoma: Clinical Practice Guideline (2024\/2025)<\/a><\/li>\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cotellic\">EMA \u2014 Cotellic: indications, product information and leaflet<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23550685\/\">Ribas et al. \u2014 Hepatotoxicity with vemurafenib + ipilimumab (2013)<\/a><\/li>\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9839305\/\">DREAMseq \u2014 Randomized treatment-sequence trial (2022\/2023)<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/research\/participate\/how\/treatment-trials\">National Cancer Institute \u2014 Participate in Cancer Treatment Trials<\/a><\/li>\n<\/ul>\n<p>Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.<\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A BRAF inhibitor: indications, the role of combination with cobimetinib, monitoring and limitations.<\/p>\n","protected":false},"author":13,"featured_media":0,"parent":5586,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-6364","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vemurafenib<\/title>\n<meta name=\"description\" content=\"Vemurafenib (Zelboraf) is a BRAF kinase inhibitor manufactured by Hoffmann-La Roche Inc., approved by the FDA for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vemurafenib\" \/>\n<meta property=\"og:description\" content=\"Vemurafenib (Zelboraf) is a BRAF kinase inhibitor manufactured by Hoffmann-La Roche Inc., approved by the FDA for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Il Melanoma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-17T10:23:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/\",\"name\":\"Vemurafenib\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/11\\\/LX4032_BRAF_inhibitor.png\",\"datePublished\":\"2011-11-24T17:54:55+00:00\",\"dateModified\":\"2026-10-17T10:23:01+00:00\",\"description\":\"Vemurafenib (Zelboraf) is a BRAF kinase inhibitor manufactured by Hoffmann-La Roche Inc., approved by the FDA for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/11\\\/LX4032_BRAF_inhibitor.png\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2011\\\/11\\\/LX4032_BRAF_inhibitor.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/vemurafenib-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medical treatment of melanoma\",\"item\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/melanoma\\\/melanomas-medical-therapy\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Vemurafenib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"name\":\"Il Melanoma\",\"description\":\"la guida alla conoscenza, prevenzione e cura del melanoma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#organization\",\"name\":\"Il Melanoma\",\"alternateName\":\"ilmelanoma.com\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"contentUrl\":\"https:\\\/\\\/www.ilmelanoma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/logo-melanoma-azzurro.png\",\"width\":300,\"height\":29,\"caption\":\"Il Melanoma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ilmelanoma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vemurafenib","description":"Vemurafenib (Zelboraf) is a BRAF kinase inhibitor manufactured by Hoffmann-La Roche Inc., approved by the FDA for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/","og_locale":"en_US","og_type":"article","og_title":"Vemurafenib","og_description":"Vemurafenib (Zelboraf) is a BRAF kinase inhibitor manufactured by Hoffmann-La Roche Inc., approved by the FDA for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.","og_url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/","og_site_name":"Il Melanoma","article_modified_time":"2026-10-17T10:23:01+00:00","og_image":[{"url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/","url":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/","name":"Vemurafenib","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/#primaryimage"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png","datePublished":"2011-11-24T17:54:55+00:00","dateModified":"2026-10-17T10:23:01+00:00","description":"Vemurafenib (Zelboraf) is a BRAF kinase inhibitor manufactured by Hoffmann-La Roche Inc., approved by the FDA for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.","breadcrumb":{"@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/#primaryimage","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2011\/11\/LX4032_BRAF_inhibitor.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/vemurafenib-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/"},{"@type":"ListItem","position":2,"name":"Medical treatment of melanoma","item":"https:\/\/www.ilmelanoma.com\/en\/melanoma\/melanomas-medical-therapy\/"},{"@type":"ListItem","position":3,"name":"Vemurafenib"}]},{"@type":"WebSite","@id":"https:\/\/www.ilmelanoma.com\/en\/#website","url":"https:\/\/www.ilmelanoma.com\/en\/","name":"Il Melanoma","description":"la guida alla conoscenza, prevenzione e cura del melanoma","publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ilmelanoma.com\/en\/#organization","name":"Il Melanoma","alternateName":"ilmelanoma.com","url":"https:\/\/www.ilmelanoma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","width":300,"height":29,"caption":"Il Melanoma"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/6364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=6364"}],"version-history":[{"count":4,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/6364\/revisions"}],"predecessor-version":[{"id":11119,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/6364\/revisions\/11119"}],"up":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/pages\/5586"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=6364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}